[Care of acute pulmonary embolism]

Area of Science:

• Cardiology
• Pulmonology
• Thrombosis

Context:

• Pulmonary embolism (PE) is a significant cause of morbidity and mortality.
• Current treatment guidelines are well-defined for mild and severe PE but lack clarity for moderate PE.
• Moderate PE presents an intermediate mortality risk (10-15%), with an unclear benefit-risk ratio for fibrinolysis.

Purpose:

• To review the current understanding and management strategies for different severities of pulmonary embolism.
• To highlight the diagnostic and prognostic challenges in moderate PE.
• To discuss ongoing research evaluating novel anticoagulants and interventions for PE.

Summary:

• Pulmonary embolism is categorized into mild, moderate, and severe forms.
• Mild PE has a favorable prognosis with established anticoagulant therapy.
• Severe PE warrants fibrinolysis alongside heparin due to high mortality; moderate PE management remains debated.
• Cardiac ultrasound and pro-BNP levels aid in risk stratification for moderate PE.
• New anticoagulants show promise primarily for mild PE, while trials are exploring treatments for severe cases.

Impact:

• Improved risk stratification and treatment protocols for moderate pulmonary embolism.
• Potential for enhanced patient outcomes and reduced mortality through optimized therapeutic strategies.
• Advancement of evidence-based guidelines for pulmonary embolism management.